Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer

NCT05215470 is registered in ClinicalTrials.gov with Hospital das Clínicas de Ribeirão Preto as lead sponsor.

NCT NCT05215470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer
Lead sponsor
Hospital das Clínicas de Ribeirão Preto
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 18, 2022
Completion date
November 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cancer metastatic